Products and Solutions

Early screening

Auxiliary diagnosis

Intervention therapy

Early risk screening for Alzheimer's disease

Key words:

Qankorey

Classification:

Products

Colloidal gold immunochromatography technology was used to qualitatively detect the Aβ concentration level in human urine, and the world's first AD urine test early screening reagent.

Product Features

Early screening:Screening of people at high risk of AD
Non-invasive:Non-invasive sampling urine test
Hypersensitivity:Detection sensitivity up to picogram level
Fast:Results can be reported 10 minutes after the sample is dropped
Convenient:Add 100uL urine, easy to detect
Accurate:The positive judgment value was 0.5ng/mL, and the detection rate was 95%

Product Application

It can be applied to the regular physical examination population over 45 years old;
Family history of dementia;
Memory impairment and suspected cognitive impairment;
Cardiovascular and cerebrovascular diseases and cerebrovascular injuries (stroke, cerebral hemorrhage, cerebral infarction, etc.);
Chronic diseases (hypertension, diabetes, hyperlipidemia, etc.), snoring and homocysteine deficiency;
Anxiety, depression, bad habits (smoking and drinking, lack of exercise in the middle of obesity, long-term lack of sleep, etc.).

Recommend Products

A biotechnology company focusing on key technologies for Alzheimer's disease (AD), a global medical challenge.